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Children and adolescents with diabetes, their families
and their care providers face the challenge of
maintaining blood glucose levels in the near to normal
range over years, day in and day out. Self-monitoring
of blood glucose (SMBG) is an important component
of therapy in patients with diabetes. SMBG provides
only intermittent glimpses of blood glucose levels,
without giving the ‘big picture’ of glucose variability
over 24 h (1), especially during the night, when blood
glucose is seldom measured (2, 3). Therefore, the
use of real-time continuous glucose monitoring (RT-
CGM) that provides continuous glucose measurements
offers the potential to help patients optimize glycemic
control and reduce the risk of hypoglycemia. RT-CGM
provides patients with a stream of interstitial glucose
measurements at 1–5 min intervals that can be used
for adjustments of the treatment regimen. A recently
published meta-analysis of randomized controlled
trials (RCTs) that aimed to determine the clinical
effectiveness of RT-CGM compared with SMBG in
young adults with type 1 diabetes (T1D), demonstrated
that CGM was associated with a significant reduction
in HbA1C, especially in those with the highest
HbA1C at baseline and in those who used the sensors
most frequently. Exposure to hypoglycemia was also
reduced during CGM. Thus, it was concluded that
the most cost-effective or appropriate use of CGM is
likely to be when targeted at people with T1D who
have continued poor control during intensified insulin
therapy and who frequently use CGM (4).
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RT-CGM can be considered as one step further in
achieving a safe way to target near normoglycemia,
and the device can serve as another step toward closing
the loop for an ‘artificial pancreas’.
While it may seem intuitively obvious that a
perfect, non-intrusive, accurate and easy-to-use device
would be of great benefit to patients, the benefits
of the current, imperfect RT-CGM systems have
been more challenging to demonstrate, especially in
pediatric patients. Thus, there is still a debate as to
whether RT-CGM can improve glycemic control,
reduce occurrence of severe hypoglycemic events,
and improve quality of life (QOL) in young patients
with diabetes. Furthermore, no clear criteria have
been established to help the physician choose the
appropriate’ patient for RT-CGM use.
To address these issues, the European Society
for Pediatric Endocrinology (ESPE), the Pediatric
Endocrine Society (PES), and the International Soci-
ety for Pediatric and Adolescent Diabetes (ISPAD)
convened a panel of expert physicians for a consensus
conference.
For each major topic area, clinical experts were
chosen to review the literature and provide evidence-
based recommendations according to criteria used
by the American Diabetes Association (ADA). Key
citations identified for each topic were assigned a level
of evidence (indicated in the reference list) and verified
by the expert panel (Table 1). This article summarizes
the consensus recommendations of the expert panel
and represents the current state of knowledge about
use of CGM in pediatric and adolescent patients.
Table 1. ADA evidence-grading system for clinical recommendations
Level of evidence Criteria
A Clear evidence from well-conducted, generalizable, randomized controlled trials (RCTs) that are
adequately powered, including:
• Multicenter trial
• Meta-analysis incorporating quality ratings
• Compelling non-experimental evidence (i.e., ‘all or none’ rule) developed by the Centre for
Evidence-Based Medicine at Oxford
• Supportive evidence from well-conducted RCTs that are adequately powered, including well-
conducted trials at one or more institutions
B Supportive evidence from well-conducted cohort studies, including:
• Prospective cohort studies or registry
• Meta-analysis of cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies including:
• RCTs with one or more major or three or more minor methodological flaws that could invalidate
the results
• Observational studies with high potential for bias
• Case series or case reports
Conflicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
Diabetes Care 2009: 32 (Suppl. 1): S1.
Types of sensors
All designed prototypes or commercially available sys-
tems can be divided into three groups based on the way
glucose measurement is carried out: non-invasive, min-
imally invasive, and invasive systems. Non-invasive
devices measure glucose with light or electromagnetic
waves without penetrating the skin. Minimally invasive
sensors are inserted through the skin and measure the
glucose concentration in the interstitial fluid of the
skin or subcutaneous tissue. Invasive sensors use intra-
venous access for measurement of blood glucose levels.
Currently, non-invasive systems are not available and
invasive systems are only available for research or
inpatient use (Biostator and Edwards Lifesciences,
Elkhart, Indiana; DexCom, San-Diego, CA). Thus,
this consensus statement focuses on pediatric use of
minimally invasive RT-CGM systems that use glucose
oxidase-based, electrochemical methods to measure
interstitial glucose concentrations. Minimally invasive
RT-CGM devices have been approved by the US Food
and Drug Administration (FDA) for use in USA or
carry Conformite´ Europe´enne (CE) marking for use
in Europe. The currently available RT-CGM devices
can be distinguished between blinded and unblinded
systems, as defined below.
Blinded technology – Holter-type retrospective
sensors
The MiniMed CGMS, its newer version the iPro™
CGM, and the GlucoDay (Menarini) system have
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been reported to serve as tools to reveal daily glucose
trends missed by SMBG, serve as educational tools
to improve metabolic control, and retrospectively
detect hypoglycemia in young patients with T1D.
They provide a means to uncover glucose patterns
and potential problems that might go undetected with
standard glucose measurements. After blinded data are
collected over a few days, the devices are returned to
the clinicians’ office and data are downloaded to a
computer; standard reports are generated which are
used by the clinicians to interpret results for their
patients.
Unblinded technology – RT-CGM
In contrast to the physician-based analysis of
retrospective data of the Holter-type sensors, RT-
CGM shifts the focus to the patient and the family,
enabling them to react to subcutaneous glucose
readings in a ‘biofeedback’ open-loop fashion. Like the
blinded systems, these devices require calibration using
fingerstick blood glucose monitoring results. Systems
are approved by the FDA for children in the age-group
above 7, whereas the European Union (EU) has no age
limit. They have also been used in young children who
participated in clinical studies evaluating the RT-CGM
devices (5, 6).
Accuracy and reliability of CGM
CGM was first available in 1999 for retrospective
analysis (MiniMed CGMS; 7), and RT-CGM was
first available in 2001 (Cygnus GlucoWatch that is
no longer in use; 8). Since their introduction, each
subsequent generation of glucose sensors has brought
increased accuracy and an improved user interface for
the patient. Accuracy needs to be assessed in terms of
the intended use of the sensor. A sensor used for trend
analysis does not need to be as accurate as a sensor
used to make insulin dose decisions.
The accuracy of current sensors is presented in
Table 2 (9–13). In this table, we have also included
accuracy data on currently available blood glucose
meters for comparison (14). A common measure of
reported accuracy is the mean or median absolute
relative difference (ARD) between sensor and reference
blood glucose levels. Using this measure, it is
common to report sensor accuracy in the hypoglycemic
[<70 mg/dL (<3.89 mmol/L)], target [70–180 mg/dL
(3.89–10 mmol/L)], and hyperglycemic ranges [>180
mg/dL (>10 mmol/L)].
Over the years, there has been a progressive
improvement in sensors as measured by their length
of wear and the percent functioning. Approved
sensors available in USA and/or Europe are currently
Table 2. Accuracy of CGM sensors compared with reference standards and home glucose meters
Meters* Sensors†
N (paired reference to meter or CGM values) 1103 1927–20 362
Reference number 13 8–12
Measurement device for reference glucose DCCT laboratory‡ YSI
Overall Median ARD% 5% 9–13%
Mean ARD% 6% 13–16%
% within ISO criteria 98–99% 76–82%§
Target range
70–180 mg/dL Median ARD% 5% 11–13%¶
(3.9–10.0 mmol/L) Mean ARD% 14–15%§
% within ISO criteria 97–99% 73–76%
Hypoglycemic
<70 mg/dL Median ARD% 8–9% 15–20%‖
(< 3.9 mmol/L) Mean ARD% 20–25%‖
% within ISO criteria 96–99% 55%
<80 mg/dL (<4.4 mmol/L) % within 20 mg/dL 57–66%
Hyperglycemic
>180 mg/dL Median ARD% 4–5% 8–11%
(>10.0 mmol/L) Mean ARD% 10–13%
% within ISO criteria 99–100% 80–91%**
*Ultra and FreeStyle meters.
†DexCom 7+, Navigator, Veo.
‡Hitachi hexokinase, University of Minnesota, DCCT central laboratory.
§Data reported as values within 20 mg/dL if <80 mg/dL and within 20% if >80 mg/dL, so the hypoglycemia criteria is less
rigid than ISO standard which assesses the percentage of sensor glucose values within ±15 mg/dL of the reference glucose
for values ≤75 mg/dL and within ±20% for glucose values >75 mg/dL.
¶For one sensor, the cutoffs were at 81–180 mg/dL and for another 80–240 mg/dL.
‖For one sensor, the cutoffs were at 8 mg/dL.
**For one sensor, the cutoffs were at 240 mg/dL.
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functioning 74 to 89% of the time after 3–7 d of
wear.
Current practice of CGM therapy in children
and adolescents
When used with current open-loop basal/bolus insulin
replacement, RT-CGM systems should provide:
(i) Improved overnight control with hypoglycemia
alarms and retrospective data to optimize
overnight basal insulin needs. In patients using
an integrated sensor-augmented pump system, the
low glucose suspend (LGS) feature may help to
prevent severe nocturnal hypoglycemic events.
(ii) Improved daytime bolus dosing with trend arrows
and hyper- and hypoglycemia alarms for real-time
adjustments, and retrospective data to optimize
carbohydrate ratios and correction doses.
(iii) Enhanced understanding of diabetes management
teaching to understand effects of different foods,
exercise, stress, and menstrual cycles on glucose
excursions.
(iv) Improved management of acute illnesses.
Over the past few years, a number of RCTs have
been undertaken to evaluate the impact of these
devices in the treatment of T1D and several important
observations have emerged regarding the indications
for RT-CGM in youth with T1D. Evidence from recent
clinical trials that have evaluated the efficacy of RT-
CGM is presented below and detailed in the following
sections.
Efficacy of RT-CGM: advantages
and disadvantages
Impact on metabolic control
Most of the RCTs that evaluated RT-CGM in patients
with T1D included children and adolescents, but only
some of them reported data for pediatric patients
separately. The GuardControl Study was one of the
first RCTs that evaluated RT-CGM; it included 54
adolescents (27 in the RT-CGM group and 27 in
the control group; 15). A post hoc intention to treat
analysis of this pediatric subpopulation demonstrated
a statistically significant difference in the reduction
of HbA1c levels after 3 months between the RT-
CGM group (−0.72 ± 1.13%) and the control group
(−0.05 ± 0.78%), adjusted p = 0.0447. The first
treat-to-target study of sensor-augmented pump (SAP)
therapy for HbA1c Reduction (Star 1) was an RCT
comparing the use of SAP therapy (n = 17) with
the use of an insulin-pump and SMBG (n = 23) in
adolescents that also showed a decrease of 0.42% in
HbA1c at 6 months that favored the SAP group, but
this difference was not statistically significant (16).
In another RCT of patient-led use of RT-CGM, 16
adolescent patients in the RT-CGM and 16 adolescent
patients in the control group (standard pump therapy)
were analyzed separately, and a statistically significant
between-group difference in HbA1c of 0.6% was found
in favor of the RT-CGM group (p = 0.025) (17).
The Juvenile Diabetes Research Foundation (JDRF)
trial on the use of RT-CGM included 27 children
and 29 adolescents in the RT-CGM group and 29
children and 38 adolescents in the control group.
There was no statistically significant difference in
the change in HbA1c between the two study groups.
However, the number of children reaching HbA1c
levels < 7% was significantly greater in the RT-
CGM as compared with the control group (15 vs.
7, respectively; p = 0.01) (18). The JDRF trial in well-
controlled patients with T1D (HbA1c ≤7%) included
18 children and 15 adolescents in the RT-CGM group
and 11 children and 18 adolescents in the control group
(19). Subjects randomized to RT-CGM were able to
maintain target HbA1c levels more effectively than
subjects randomized to the control group in that study
but the data for the pediatric subjects were not reported
separately.
The study of SAP therapy from the onset of
childhood T1D (ONSET study) was a pediatric trial
that compared the use of SAP with insulin-pump alone
from the disease onset in 80 children in the SAP group
and 80 children in the control group. It showed no
significant difference between the two groups in HbA1c
after 12 months, but the mean amplitude of glycemic
excursion (MAGE) was significantly diminished in the
SAP group (−0.66, p < 0.04) (5). An RCT in well-
controlled patients (HbA1c < 7.5%) that focused on
time spent in hypoglycemia and included children and
adolescents in the RT-CGM group (n = 27) and the
control group (n = 26), found that the between-group
difference in HbA1c at 6 months (adjusted for baseline
HbA1c, center, and age group) was significantly
different for the whole study population (mean 6.69
vs. 6.95%, difference in means −0.27, 95% confidence
interval (CI) −0.47 to −0.07, p = 0.008) (20).
The third study of SAP therapy for HbA1c
Reduction (Star 3) was a large RCT comparing
SAP with the use of multiple daily injections (MDI)
with insulin analogues and included 78 children and
adolescents in the SAP group and 78 children and
adolescents in the MDI group (21, 22). At 12 months,
the pediatric between-group difference in HbA1c of
0.5%, in favor of the SAP group was statistically
significant (p < 0.001) along with significantly more
children and adolescents in the SAP group reaching the
age-specific target HbA1c (between-group difference
25%, p < 0.005). Rates of severe hypoglycemia and
diabetic ketoacidosis (DKA) were low and did not
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differ between the two treatment groups. The study
was not, however, designed to differentiate the effect
of RT-CGM from the effect of the use of insulin pumps.
The Diabetes Research in Children Network
(DirecNet) conducted several non-randomized cohort
studies that demonstrated the efficacy of RT-CGM
in improving metabolic control in the pediatric
population. One DirecNet study reported 13 wk of use
of RT-CGM in 30 children and adolescents aged 3–18
yr using insulin pumps (23). Mean HbA1c improved by
0.3% (7.1 ± 0.6% at baseline to 6.8 ± 0.7% at the end;
p = 0.02), with an 8% increase of glucose values within
a 71- to 180-mg/dL interval (from 52 to 60%; p = 0.01)
and without any severe hypoglycemic events. HbA1c
levels did not increase in the three patients with baseline
values ≤7.0% (mean 6.6 ± 0.4%), whereas in the 15
patients with baseline HbA1c levels >7.0%, HbA1c
levels decreased from 7.6 ± 0.4% to 7.0 ± 0.7%, with
no significant change in time spent in hypoglycemia.
Another DirecNet study assessed the 13-wk use of RT-
CGM in 27 children aged 4–17 yr using MDI with
insulin glargine (24). Mean HbA1C decreased by 0.6%
(from 7.9 ± 1.0% at baseline to 7.3 ± 0.9% at the
end, p = 0.004), with a bigger drop in patients with
baseline HbA1C levels >7.5%. Additionally, MAGE
also decreased significantly by 20 mg/dL (from 147
to 127 mg/dL, p = 0.001). Both DirecNet trials were
extended for an additional 13 wk of follow-up; HbA1c
increased close to the baseline levels, whereas MAGE
remained lower throughout the 26-wk observational
period (25).
A recently published large retrospective observa-
tional study reporting on 129 pediatric patients using
SAP compared to 493 patients treated with CSII with
no CGM, demonstrated that in ‘real-life’ setting the
CGM permits a greater decrease in HbA1C after a
mean follow-up of 1.6 yr (26).
Impact on hypoglycemia
Only one RCT reported significantly more severe
hypoglycemia in the RT-CGM group as compared
with the SMBG group (11 vs. 3 events, respectively)
(16); however, the ages of the eight patients who had 11
events of severe hypoglycemia in the RT-CGM group
was not indicated. All other RCTs reported no increase
in severe hypoglycemia with or without a concomitant
decrease in HbA1c (15, 17–21, 27).
The rates of severe hypoglycemia in pediatric
patients in the JDRF (18) and Star 3 (21) studies
are shown in Table 3. In both of these studies,
the rates of severe hypoglycemia did not differ
by treatment group and were lower than expected.
For comparison, the rate of severe hypoglycemia in
intensively treated adolescents in the Diabetes Control
and Complications Trial was 86 events per 100 patient
years (28).
Notably, one RCT in pediatric patients reported
a significant decrease in severe hypoglycemia in the
group using SAP compared with the group using
insulin-pump therapy with SMBG (0 vs. 4, respectively)
(5). The JDRF trial in well-controlled patients
demonstrated a significant decrease in time spent at
<60 mg/dL (median, control vs. RT-CGM at 26 wk:
35 vs. 18 min/d, respectively) in the RT-CGM group
in the total study population without results for the
pediatric subpopulation being reported separately (19).
Another trial in well-controlled patients demonstrated
a significant decrease in time spent at<70 mg/dL (mean
± SD, control vs. RT-CGM at 26 wk: 1.60 ± 2.02 vs.
0.91 ± 0.81 h/d, p < 0.01, <63 mg/dL (0.97 ± 1.55
vs. 0.48 ± 0.57 h/d, p < 0.03) and <55 mg/dL (0.41
± 0.48 vs. 0.22 ± 0.34 h/d, p < 0.05), along with
a significant decrease in the number of hypoglycemic
excursions <63 mg/dL and <55 mg/dL during the
night (0.21 ± 0.32 vs. 0.30 ± 0.31, p = 0.009 and
0.13 ± 0.30 vs. 0.19 ± 0.19, p = 0.01, respectively)
for the whole study population, and a 64% statistically
significant reduction in the time spent at <63 mg/dL
during the night for the pediatric subpopulation (10–17
yr of age) according to a post hoc per-protocol analysis
(p < 0.001) (21).
Sensor use and efficacy
In a large retrospective observational study (26), the
median glucose sensor usage of 13.4 d/month was
Table 3. HbA1c (at study end) and rates of severe hypoglycemia (events/100 patient years) in major RCTs of pediatric patients
Experimental group Control group
Study (reference) HbA1c (%) Hypoglycemia rate Hb1Ac (%) Hypoglycemia rate p-Value for hypoglycemia
Star 1 (15) 8.0 12.5 8.2 16.7 NS
JDRF (8– 14 yr) (17) 7.6 17.9 7.7 24.4 0.64
JDRF (15– 24 yr) (17) 7.8 17.9 7.7 23.9 0.64
JDRF (8– 17 yr)* (17) 7.9 11.2 NA NA NA
Star 3 (20) 7.9 9.0 8.5 5 0.35
NA, not applicable; NS, not significant.
*RT-CGM group only over 12 months of use.
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sufficient for a significant improvement in HbA1c
of 0.9%.
However, most RCTs reported an association
between the amount of sensor use and its efficacy
in improving metabolic control (15–19, 21, 27, 29). In
a separate analysis of the 80 pediatric patients aged
8–17 yr in the JDRF RCT (30), 42% of subjects were
able to use CGM 6 or more days per week during the 6-
month randomized trial; they lowered HbA1c levels by
0.8% vs. no change in the subjects who used the sensor
less frequently. Moreover, the 0.8% improvement in
HbA1c was maintained during the 6-month extension
phase of the study in only the 21% of subjects who
continued to use the sensor on an almost daily basis;
whereas HbA1c levels reverted to baseline levels in the
21% of subjects who stopped wearing the sensor daily.
Such a decline in sensor use has proved to be the limiting
factor for the efficacy in the pediatric age group in other
studies (25, 27).
Intermittent use of real-time or retrospective CGM
When the MiniMed CGMS device was first introduced
for 3-d retrospective analysis of plasma glucose profiles,
investigators quickly showed that this method of
glucose monitoring revealed patterns of postmeal
hyperglycemia and nocturnal hypoglycemia that were
not evident during standard SMBG testing in children
with T1D (1). Several small clinical trials suggested
that even one or two uses of the MiniMed CGMS
device could lead to treatment adjustments that had
long-lasting improvements in metabolic control of T1D
(31–33). The validity of these findings has been cast in
doubt by the results of RT-CGM studies that indicate
the need for near-daily use of the devices to obtain
and maintain lowering in HbA1c levels. Indeed, a
recent meta-analysis (34) of five RCTs in pediatric
patients (6, 33, 35–37) indicated that technology which
does not allow for real-time assessment of glycemia
by the patient but only allows for a retrospective
analysis by the doctor does not lead to a significant
improvement in HbA1c levels. Although the trials with
retrospective sensors have already led to considerable
practical experience with this technology, they should
be reserved for special indications (38).
Recommendations
(i) RT-CGM can be used effectively for lowering
HbA1c (15, 17, 21, 23, 24), reaching target HbA1c
(18), and reducing the MAGE (5, 25) in the
pediatric population with T1D without increasing
the frequency of severe hypoglycemia;
(ii) RT-CGM can be used effectively for reducing
severe hypoglycemia (5) and shortening the time
spent in hypoglycemia (20) in the pediatric
population with T1D;
(iii) The effectiveness of RT-CGM in the pediatric
population with T1D is significantly related to the
amount of sensor use (17, 21, 30, 39). Therefore,
efforts for increased adherence with sensor use are
paramount in this age group;
(iv) SAP is an effective means to treat youth of all ages
at the onset of the disease (5);
(v) SAP treatment is effective in lowering HbA1c
levels in children and adolescents with T1D who
have elevated HbA1c values on MDI therapy
using standard blood glucose monitoring (19, 20);
(vi) Intermittent, retrospective or real-time CGM may
be of use in children and adolescents with T1D
to detect the dawn phenomenon, postprandial
hyperglycemia, asymptomatic, and nocturnal
hypoglycemia and in evaluating the effects of
major changes in treatment regimens (31–33);
(vii) The development of more pediatric-oriented
devices for RT-CGM is warranted along with
additional well-designed RCTs in the whole
pediatric age-group spectrum.
Safety of CGM in children and adolescents
Inaccurate sensor glucose readings due to errors in
calibration or general sensor malfunctioning should
not lead to errors in insulin dosing as patients/families
are instructed in the need to use data from standard
SMBG before insulin administration. Unnecessary
treatment of hypoglycemia from RT-CGM glucose
results is also unlikely owing to routine instructions to
patients/families to check blood glucose levels before
treating presumed low glucose values noted by RT-
CGM (unless clinical symptoms dictate the need to
treat before blood glucose confirmation).
Severe hypoglycemia or severe hyperglycemia with
DKA rates should not be any greater than in routine
care and may be reduced with the aid of RT-CGM data
and CGM alarms for high and low glucose readings.
Data from RCTs indicated very low rates of
DKA and severe symptomatic (not biochemical)
hypoglycemia, and there were no differences between
RT-CGM and SMBG control groups.
In Star 1, there were 11 severe hypoglycemic events
in the RT-CGM group vs. 3 in the SMBG group
(p = 0.04). This was thought to be due to lack of
patient response to low glucose alarms and/or possible
‘insulin stacking’ from overzealous insulin treatment
by patients (30).
Routine rates of severe hypoglycemia in the modern
era of pediatric diabetes management are 20–30
events/100 patient-years (40–42) and appear to be
lower with CGM use at 8 events/100 patient-years
in the 15- to 24-year-old group and 13 events/100
220 Pediatric Diabetes 2012: 13: 215–228
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patient-years in the 8- to 14-year-old group (43).
Rates of severe hypoglycemia and DKA were low
and did not differ between CGM and SMBG groups in
all three age groups in the JDRF RT-CGM study
(9–15, 16–21, 23–25, 30, 43) during the 6-month
RCT (18).
Rates of severe hypoglycemia and DKA were similar
in Star 3 in the SAP group and MDI/SMBG group (21).
Rates of sensor site infections appear to be low;
only two reported events of cellulitis at the sensor
site in the 8- to 14-year-old age group in the
JDRF-CGM RCT (18).
However, it should be noted that there are some
safety issues relating to skin irritation from sensor
adhesives, sensor site infections, and broken-off or
retained sensor tips in the subcutaneous space.
Recommendations: level E
(i) Initial and ongoing education regarding the
lag time and need to confirm CGM glucose
results with standard SMBG before insulin
administration and when it is possible and
clinically safe, before treatment of hypoglycemia;
(ii) Initial and ongoing education regarding the
optimal approach and timing of sensor calibration
should help ensure optimal sensor performance;
(iii) Initial and ongoing education regarding sensor
site care with attention to using sensors according
to manufacturers’ recommendations, including
the need for fingerstick blood sugars for all
treatment decisions.
Considerations of patient selection for use
of CGM in children and adolescents
As mentioned previously, observational and RCT
studies in the pediatric age group found improvement
in metabolic control with the use of CGM (1, 15–18, 21,
23, 31–33). Most of the RCT studies including pediatric
T1D patients (17, 21, 24, 39) have demonstrated
that the frequency of the CGM use was significantly
associated with the effect of lowering HbA1C levels. In
the JDRF-CGM trial, the only baseline characteristic
that predicted near daily CGM use in pediatric
patients was frequent daily SBGM before entering the
trial (39).
Alarms on the CGM for pending low glucose levels,
as well as for reaching a specific low glucose threshold,
are both helpful in preventing severe hypoglycemia,
especially during the night. Unfortunately, data suggest
that youth do not respond to approximately 71% of
alarms during sleep (42). The JDRF-CGM study group
reported that in patients with T1D aged 8–18 yr who
have achieved HbA1c levels <7%, the RT-CGM use
reduced the frequency of hypoglycemia and helped
maintain HbA1c levels <7% compared with standard
SBGM over a 6-month study period (19).
Limited data from small observational studies
indicate that the CGM can be used successfully in
patients <8yr old (3, 44). Physically, patients must
have enough subcutaneous tissue to incorporate sensor
wear.
Studies of CGM use in pediatrics have shown that
youth can maintain adherence to wearing the device
for 3 months, and outcomes of CGM use with both
continuous subcutaneous insulin infusion (CSII) and
MDI have been similar (23–25).
Currently, not enough direct evidence is available to
propose the specific features to identify patients likely
to experience the best outcomes with CGM.
The decision to use CGM should be made jointly by
the child, parents, and diabetes team. Most pediatric
patients with T1D are potential candidates for use of
CGM, without a lower age limit for initiating it, and
CGM should be available for any pediatric patient
with T1D who wants to try it. CGM can be used with
either MDI or CSII (23, 24).
On the basis of the evidence presented previously,
CGM should be considered in children and adolescents
with T1D and in the following conditions:
Therapeutic use (continuous use)
(i) Patients who are doing frequent blood glucose
testing (39);
(ii) Patients who have severe hypoglycemic episodes
(5);
(iii) Patients who have hypoglycemic unawareness
especially in young children (45);
(iv) Patients who have nocturnal hypoglycemia (2,
46, 47);
(v) Wide glucose excursions regardless of HbA1c
levels (48–50);
(vi) Young children with diabetes with large blood
glucose variability and difficulty in identifying
hypoglycemic episodes (3, 44);
(vii) Patients who have suboptimal glycemic control
with HbA1c exceeding target range (15–17, 21,
32, 33, 36, 51);
(viii) Patients with T1D and HbA1c levels <7% (with
the aim to maintain target glycemic control, while
limiting the risk of hypoglycemia) (19).
Other circumstances in which CGM may be
beneficial are described below.
Diagnostic/intermittent use
CGM may also be beneficial with diagnostic/
intermittent use. However, at this time, there are not
enough evidence-based data, and more data have to
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be acquired. Nonetheless, it has been suggested that
intermittent use of CGM may be of benefit in:
(i) Detection of nocturnal hypoglycemia or hyper-
glycemia (e.g. dawn phenomenon);
(ii) Individuals in whom the causes of persistently
high HbA1c levels are unclear for detection of
hyperglycemic peaks not identified by SMBG;
(iii) Making changes to patients’ diabetes treatment
regimen (e.g., changing of insulin type or
switching from MDI to CSII or vice versa)
(27, 52, 53);
(iv) Special situations, such as: sport, eating outside
the home, trying new foods; traveling or driving;
or patients with severe fear of hypoglycemia;
(v) Infants with neonatal hypoglycemia (54);
(vi) Intensive care unit for glucose monitoring;
(vii) Cystic fibrosis-related diabetes (55–58);
(viii) Detection of hypoglycemia in metabolic diseases
(59);
(ix) Monitoring glycemia in research settings;
(x) Motivated families of young children, especially if
the patient suffers from recurrent hypoglycemia.
Patient perception of the benefits and hassles
of CGM
Consistent usage of CGM has been difficult to
achieve in clinical trials and in routine care, especially
among children and adolescents. To identify ways
to reduce barriers to more consistent CGM use, it
is important to understand how patients perceive
the benefits and hassles of CGM and how these
perceptions are associated with frequency of use. To
evaluate this question, youth with T1D in the JDRF
RT-CGM trials and their parents completed the
CGM Satisfaction Scale (CGM-SAT) developed by
DirecNet (60) after 6 months of sensor use. CGM-SAT
assesses impact of RT-CGM on diabetes management,
family relationships, and emotional and behavioral
characteristics. The psychometric properties cover
two subdomains: benefits and hassles; a higher
score reflects greater benefits or fewer hassles with
RT-CGM use.
An important finding of the study was the rela-
tionship between perceived satisfaction and frequency
of RT-CGM use (61). Youth who were frequent
RT-CGM users and their parents reported greater
satisfaction and had higher scores on the two subscales
compared with infrequent users. Of particular note, the
greatest differences between the two groups involved
the hassle items. This suggests that patients using RT-
CGM who perceive it to be beneficial and wear the
device frequently are less bothered by the hassles,
while those patients who wear the device infrequently
focus more on the hassles than the benefits. In response
to open-ended questions, many participants appreci-
ated that RT-CGM provided previously unavailable
data on glucose trends/graphs, as well as the ability
to self-correct out-of-range glucose levels in real-time.
Conversely, between a quarter and a third of youth
reported challenges with CGM alarms, insertion, and
site/body issues related to the need to wear the device.
Recommendations
(i) A pediatric multidisciplinary diabetes team
experienced in RT-CGM use should focus on
how to adequately select, train, manage, and
motivate the child/adolescent with diabetes and
parents/guardians to optimize benefits from RT-
CGM. Overall, an educator support system and
device trainer are crucial for success in wearing
the RT-CGM device;
(ii) The youth with diabetes must have a personal
interest in wearing the RT-CGM and not be a
passive accomplice to a parental decision;
(iii) Youth with RT-CGM need help from par-
ents/guardians with changing the sensor, respond-
ing alarms, making dose changes, and trou-
bleshooting problems;
(iv) The RT-CGM data have to be reviewed with
the patients and parents to make conclusions
regarding diabetes management and to make the
proper changes.
Skills that need to be taught for RT-CGM use
To ensure the success of patients on RT-CGM,
treatment guidelines have to be provided to patients to
allow them to safely and effectively take advantage of
the information provided by the RT-CGM (62).
Proper training is necessary for patients to use
RT-CGM correctly, and maintaining a high level of
contact with the families during the first months of
wear (62, 63).
QOL with RT-CGM
QOL assesses the physical and mental health of individ-
uals and is often considered in terms of how life is nega-
tively affected by chronic illness or by treatment. QOL
measures extend beyond traditional morbidity and
mortality and include consideration of physical and
emotional function as well as general life satisfaction.
Assessment of QOL includes generic measures and
disease-specific measures. In pediatric settings, QOL
can include self-reported measures from older children
and teenage pediatric patients and proxy reports of
youth QOL as reported by parents/guardians (64–66).
Generic measures of QOL allow for comparisons
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across populations with health and disease as well as
across cultures/regions. These measures are often insen-
sitive to particular aspects of disease and its treatment.
Disease-related QOL measures tend to be more sensi-
tive and specific to the disease and its management. A
combination of generic and disease-specific QOL mea-
sures allows for monitoring of a patient’s health status
over time in response to management or interventions.
Dimensions of QOL include positive well-being,
negative well-being, worries, and social burden.
Generic measures of health-related QOL for pediatric
patients, in general, include physical and psychosocial
domains with school, emotional, and social arenas
included in the psychosocial domains. Disease-related
measures include assessment of treatment convenience,
interference, and satisfaction. Another dimension of
QOL can include assessment of disease burden on the
youth and on the parents/guardians. Finally, in the
management of T1D, fear of hypoglycemia is another
area that warrants assessment regarding a patient’s
perception of QOL.
Does RT-CGM confer additional psychosocial
stress to the child and family?
Generic QOL measures obtained from youth with T1D
and from parent proxy reports appear to be similar
to reports from normative samples of youth from a
US study (67), while parent proxy report from an
Australian sample reported lower QOL in youth with
T1D compared with a normative, age matched sample
(14). However, the QOL reported by the adolescents
with T1D was similar to the normative population of
adolescent youth in that sample (68). Thus, reports
of generic QOL in youth with T1D may be similar
to reports of non-diabetic youth and may be age-
dependent.
Overall, general QOL in youth with T1D appears to
be associated with glycemic control in cross-sectional
studies. Higher QOL was associated with lower HbA1c
(69–72), although one report found no association
between QOL and HbA1c (68).
A cross-sectional survey of 457 families of youth
with T1D indicated that families are likely to elect
RT-CGM for youth who use an insulin pump, check
blood glucose levels more than six times daily, and
have parental worry about either high or low blood
glucose levels. Age of the child and HbA1c were not
related to parental interest in RT-CGM (73).
RT-CGM use in pediatric patients could impact
QOL in many ways; the wealth of glucose data
resulting from RT-CGM could add distress after
observing out-of-range data or could reduce concerns
by providing real-time results. Nevertheless, RT-CGM
use does not appear to negatively impact QOL
according to youth self-reports and parent proxy
reports, using both generic and diabetes-specific
measures (5, 21, 74). Specifically:
(i) There was no change in reported fear of
hypoglycemia among youth or their parents
with RT-CGM use compared with SMBG (74).
Adults with T1D have reported reduced fear of
hypoglycemia with RT-CGM use (74);
(ii) There was no increase in parent reports of diabetes
burden with RT-CGM use compared with parent
reports of diabetes burden with SMBG (74);
(iii) Satisfaction with RT-CGM has been assessed
with a validated questionnaire created specifically
to assess RT-CGM technology satisfaction (75).
In general, satisfaction with RT-CGM has been
relatively high, with mean scores about 4 (on a 1-
to 5-point scale) (76). RT-CGM satisfaction was
related to RT-CGM use, with mean RT-CGM
satisfaction scores being higher with greater RT-
CGM use (or with lower HbA1c) (74);
(iv) Barriers to RT-CGM use were reported by youth
with T1D and their parents. Youth and their
parents reported barriers related to RT-CGM
alarms, body issues, and pain at insertion (77);
(v) Benefits to RT-CGM use were reported by youth
with T1D and their parents. Youth and parents
reported benefits related to glucose trend graphs,
detection of low blood glucose levels, availability
of RT-CGM data, and ability to self-correct out-
of-range glucose levels (77).
Quality and frequency of pediatric diabetes
care–what is required for RT-CGM implementation
and ongoing use with respect to pediatric diabetes
team visits, education for RT-CGM use (i.e., extra
education visits), etc.?
(i) Quality of education: RT-CGM education is best
provided by clinicians experienced in pediatric
diabetes management;
(ii) Frequency of education and follow-up visits
during RCTs of RT-CGM vs. SMBG alone, not
RCTs of SAP vs. SMBG:
(a) Randomized phase of the JDRF-CGM trial:
The study groups had four extra visits and
six extra phone calls initiated by the diabetes
team during the 6-month RCT at times 0, 1,
4, 8, 13, 19, and 26 wk for the implementation
of CGM. There was one phone call between
each visit (18). During the 6-month extension
phase of the CGM group in the JDRF trial
there were visits every 3 months, as would be
expected for routine follow-up diabetes care.
During the 6 months cross over from
SMBG to RT-CGM in the JDRF trial
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there were two extra visits and two calls
by the diabetes team at the start of
RT-CGM followed by visits at 3 and 6
months (18);
(b) GuardControl: During the 3-month study,
there were two extra visits. Visits occurred
at baseline, 10 d, 1 month, and 3 months (15);
(c) RealTrend: During the 6-month study, there
were visits at baseline, 3 d, 12 d, 1 month,
3 months, and 6 months, amounting to three
extra visits (27);
(d) O’Connell: In this 3-month multicenter RCT
comparing SAP with standard pump therapy,
there were no additional visits after a baseline,
standardize education visit in the use of
RT-CGM (17);
(e) Star 1: In the 6-month study, there was training
in intensive diabetes management, RT-CGM
use, and data interpretation, with increased
interactions between subjects and clinicians
throughout the study period (16).
Recommendations
(i) There should be an initial informational session
about RT-CGM before prescription for general
RT-CGM education, provision of realistic
expectations, and device selection. This session
could be in a group or as an individual visit;
(ii) There should be a minimum of one extra visit
for RT-CGM start-up (insertion, site care, alarm
setting, dose adjustments, trend analysis, data
analysis, nutritional changes, etc.) by RT-CGM
educator specialists;
(iii) Following RT-CGM implementation, there
should be an additional follow-up visit within
1–2 wk of RT-CGM initiation to download data
and review RT-CGM settings (alarms), use, and
insulin regimen;
(iv) There should be consideration for extra contact(s)
to encourage ongoing RT-CGM use and to
address potential barriers to RT-CGM use in the
pediatric population.
Cost-effectiveness of CGM therapy
There are no published cost-effectiveness analyses
or cost-benefit studies analyzing intermittent or
continuous CGM in children or adolescents with T1D
and such analyses are needed. The published cost-
effectiveness analysis that was done based on the
JDRF trial by means of the internet-based, interactive
computer simulation model to determine the long-term
health outcomes and economic consequences of type
1 and type 2 diabetes (CORE model) was restricted
to adults with T1D who had baseline HbA1c levels
≥7.0%. Patients in the 8–14 and 15–24-year-old age
groups in that study were excluded from these cost-
effectiveness analyses because the RT-CGM groups
did not achieve a significant lowering of HbA1c levels
compared with controls. It concluded that ‘Long-term
projections indicate that CGM is cost-effective among
type 1 diabetic patients at the $100 000/ quality-adjusted
life-year (QALY) threshold, although considerable
uncertainty surrounds these estimates’ (78). Comparable
calculations from presently unpublished analyses have
found an even better cost-effectiveness ratio compared
with SMBG in Sweden (36 000–52 000¤ /QALY) based
on the RealTrend study data and in the Netherlands
(21 000 ¤/QALY) based on the GuardControl trial.
Both countries decided to reimburse RT-CGM based
on these data.
Conclusions
(i) Real-time sensors are proven to be cost-effective in
well-controlled children and adults (HbA1c levels
<7.0%);
(ii) Real-time sensors have positive effects on glycemic
control with evidence of cost-effectiveness vs.
SMBG in adults with HbA1c levels >7.0%, and
likely in children with frequent use;
(iii) Improving RT-CGM technology and semi-
automated hybrid or full-closed loop systems
are rapidly emerging and make a constant re-
evaluation of the cost-effectiveness of the most
recent technology mandatory.
RT-CGM as part of the closed-loop system
and future research opportunities
Treating T1D in children is challenging for patients,
their family members, and medical staff, and keeping
the blood glucose levels constant within the desired
(target) range day and night is almost an impossible
mission. Thus, the development of an automatic
system that will decrease patient burden and improve
glucose control is an unmet medical need. The
typical closed-loop system has to be based on a
continuous glucose sensor, insulin pump, and a
computerized algorithm; technologies that are already
available.
The first step toward closing the loop which is
already commercially available outside the USA is
an automatic suspension of the insulin delivery when
the patient is in the hypoglycemic range and does not
respond to the system alarm. It has been found that
there is often a prolonged period of hypoglycemia
preceding nocturnal hypoglycemia-associated seizures
(79) which might be prevented by suspending basal
insulin infusion. In addition, it has been shown that
suspension of subcutaneous insulin delivery for up
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to 2 h is not associated with ketosis or rebound
hyperglycemia (79, 80). In a preliminary user trial
conducted in the UK and Germany, using the LGS
feature was shown to be safe and effective at reducing
duration of hypoglycemia and was well accepted by
the users (81).
Recommendation
An automatic system that will safely control blood
glucose levels in children with diabetes within the
desired range is currently an unmet medical need.
The technology and algorithms necessary to reach this
goal are currently evolving. While the ultimate goal
is a fully automated system, a step-wise approach
could provide clinically meaningful solutions. Insulin
suspension during hypoglycemia has shown promising
preliminary results in children and should be further
studied for its safety and efficacy as it is the first step
toward closing the loop.
Conclusions
The unifying theme of trials investigating the usefulness
of CGM technology is that in order to reap benefits, the
device must be worn on a near-daily basis. Education
is a critical component to ensure that patients and
their families are able to realize the full potential
of this therapeutic tool. Families first need to be
educated on what information a sensor can, and cannot
provide them. Once the decision is made to pursue
sensor therapy, the discussion turns to which device
is right for a particular patient and family. Ensuring
adequate education for the patients, and their family,
on the use of the device is critical for success. It may
be possible to encourage more frequent RT-CGM
usage by focusing on the benefits of the technology
and in preemptive counseling that provides realistic
expectations and effective strategies to overcome the
difficulties in using these devices. Moreover, as industry
introduces improved RT-CGM systems that make
them less painful and easier to use, and adds features
like the LGS, it is reasonable to expect that patients
will use RT-CGM more consistently, which, in turn,
should result in a greater improvement in metabolic
control of T1D.
The vast majority of the studies cited on RT-CGM
use in children and adolescents use a multidisciplinary
trained team that usually is not available to the non-
academic pediatric endocrinologist. This may be a
caveat to prescribing RT-CGM.
In summary, based on the available evidence and the
experience of the expert panel, the use of RT-CGM
may be appropriate for motivated children and youth
of all ages provided that appropriate support personnel
are available.
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